Cerebral changes occurring in arginase and dimethylarginine dimethylaminohydrolase (DDAH) in a rat model of sleeping sickness

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Amrouni, Donia ^a   Meiller, Anne ^a   Gautier Sauvigné, Sabine ^a   Piraud, Monique ^b   Bouteille, Bernard ^c   Vincendeau, Philippe ^d   Buguet, Alain ^a   Cespuglio, Raymond ^a  

^a UNIVERSITÉ LYON 1   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d Institut de recherche pour le développement   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; DIMETHYLARGININASE; DIMETHYLARGININASE 1; DIMETHYLARGININASE 2; HYDROLASE; MESSENGER RNA; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG; AMIDASE; AMINO ACID; ISOENZYME;

AFRICAN TRYPANOSOMIASIS; AMINO ACID ANALYSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFECTION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIQUID CHROMATOGRAPHY; MALE; MORPHOMETRICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD; BRAIN; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MASS SPECTROMETRY; METABOLISM; PARASITOLOGY; PATHOLOGY; TRYPANOSOMA BRUCEI; WISTAR RAT;

ANIMALIA; RATTUS; TRYPANOSOMA BRUCEI BRUCEI;

AMIDOHYDROLASES; AMINO ACIDS; ANIMALS; ARGINASE; BIOSYNTHETIC PATHWAYS; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; ISOENZYMES; MALE; MASS SPECTROMETRY; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; RNA, MESSENGER; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 79952406130     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016891     Document Type: Article

References (42)

1. Buguet A, Bourdon L, Bouteille B, Cespuglio R, Vincendeau P, et al. (2001) The duality of sleeping sickness: focusing on sleep. Sleep Med Rev 5: 139-153.
2. Amrouni D, Gautier-Sauvigné S, Meiller A, Vincendeau Ph, Bouteille B, et al. (2010) Cerebral and peripheral changes occurring in nitric oxide (NO) synthesis in a rat model of sleeping sickness: Identification of brain iNOS expressing cells. PloS One 5, e9211: 1-10.
3. Alderton WK, Cooper CE, Knowles RG, (2001) Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615.
4. Gobert AP, Daulouede S, Lepoivre M, Boucher JL, Bouteille B, et al. (2000) L-arginine availability modulates local nitric oxide production and parasite killing in experimental trypanososmiasis. Infect Immun 68: 4653-4657.
5. Antoine-Moussiaux N, Magez S, Desmecht D, (2008) Contributions of experimental mouse models to the understanding of African trypanosomiasis. Trends Parasitol 24: 411-418.
6. Yu H, Iyer RK, Kern RM, Rodriguez WI, Grody WW, et al. (2001) Expression of arginase isoforms in mouse brain. J Neurosci Res 66: 406-422.
7. Hecker M, Nematollahdi H, Hey C, Busse R, Racké K, (1995) Inhibition of arginase by N-hydroxy-L-arginine in alveolar macrophages: implications for the utilization of L-arginine for nitric oxide synthesis. FEBS Lett 359: 251-254.
8. Tsikas D, Böger RH, Sandmann J, Bode-Böger SM, Frölich JC, (2000) Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett 478: 1-3.
9. Tran CT, Fox MF, Vallance P, Leiper JM, (2000) Chromosomal localization, gene structure, and expression pattern of DDAH1: Comparison with DDAH2 and implications for evolutionary origins. Genomics 68: 101-105.
10. Leiper J, Murray-Rust J, McDonald N, Vallance P, (2002) S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci U S A 99: 13527-13532.
11. Duleu S, Vincendeau P, Courtois P, Semballa S, Lagroye I, et al. (2004) Mouse strain susceptibility to trypanosome infection: An arginase-dependent effect. J Immunol 172: 6298-6303.
12. Bradford MM, (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
13. Liu P, Smith PF, Appleton I, Darlington CL, Bilkey DK, (2003) Nitric oxide synthase and arginase in the rat hippocampus and the entorhinal, perirhinal, postrhinal, and temporal cortices: Regional variations and age-related changes. Hippocampus 13: 859-867.
14. Prescott LM, Jones ME, (1969) Modified Methods for the determination of carbamyl aspartate. Anal Biochem 32: 408-419.
15. Meiller A, Alvarez S, Drané P, Lallemand C, Blanchard B, et al. (2007) p53-dependent stimulation of redox-related genes in the lymphoid organs of gamma-irradiated mice: identification of haeme-oxygenase 1 as a direct p53 target gene. Nucleic Acids Res 20: 6924-6934.
16. Piraud M, Vianey-Saban C, Bourdin C, Acquaviva-Bourdain S, Boyer S, et al. (2005) A new reversed-phase liquid chromatographic/tandem mass spectrometric method for analysis of underivatised amino acids: evaluation for the diagnosis and the management of inherited disorders of amino acids metabolism. Rapid commun. Mass Spectrom 19: 3287-3297.
17. Schwedhelm E, Tan-Andrese J, Maas R, Riederer U, Schulze F, et al. (2005) Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 51: 1268-1271.
18. Swamy M, Sirajudeen KN, Chandran G, (2009) Nitric oxide (NO), citrulline-NO cycle enzymes, glutamine synthetase, and oxidative status in kainic acid-mediated excitotoxicity in rat brain. Drug Chem Toxicol 32: 326-331.
19. Durante W, Johnson FK, Johnson RA, (2007) Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol 34: 906-911.
20. Newport GR, Page CR 3rd, Ashman PU, Stibbs HH, Seed JR, (1977) Alteration of free serum amino acids in voles infected with Trypanosoma brucei gambiense. J Parasitol 63: 15-24.
21. Uzonna JE, Kaushik RS, Gordon JR, Tabel H, (1999) Cytokines and antibody response during Trypanosoma congolense infections in two inbred mouse strains that differ in resistance. Parasite Immunol 21: 57-71.
22. De Baetselier P, Namangala B, Noël W, Brys L, Pays E, et al. (2001) Alternative versus classical macrophage activation during experimental African trypanosomiasis. Int J Parasitol 31: 575-587.
23. Müller S, Liebau E, Walter RD, Kraut-Siegel RL, (2003) Thiol-based redox metabolism of protozoan parasites. Trends Parasitol 19: 320-328.
24. Masocha W, Rottenberg ME, Kristensson K, (2007) Migration of African trypanosomes across the blood-brain barrier. Physiol Behav 92: 110-114.
25. Abolarin MO, Evan DA, Tovey DG, Ormerod WE, (1982) Cryptic stage of sleeping-sickness trypanosome developing in choroid plexus epithelial cells. Br Med J 285: 1380-1382.
26. Ormerod WE, Venkatesan S, (1971) The occult visceral phase of mammalian trypanosomes with special reference to the life cycle of Trypanosoma (Trypanozoon) brucei. Trans R Soc Trop Med Hyg 65: 736-741.
27. Van Marck EA, Le Ray D, Beckers A, Jacob W, Wery M, et al. (1981) Light and electron microscope studies on extracellular Trypanosoma brucei gambiense in the brain of chronically infected rodents. Ann Soc Belg Med Trop 61: 57-78.
28. Mattern P, Mayer G, Felici M, (1972) Existence of amastigote forms of Trypanosoma gambiense in the choroidal plexal tissue of experimentally infected mice. C R Acad Sci D 274: 1513-1515.
29. Stoppini L, Buchs PA, Brun R, Muller D, Duport S, et al. (2000) Infection of organotypic slice cultures from rat central nervous tissue with Trypanosoma brucei brucei. Int J Med Microbiol 290: 105-113.
30. Cespuglio R, Colas D, Gautier-Sauvigné S, (2005) Energy processes underlying the sleep-wake cycle. In: Velluti R, Parmeggiani PL, editors. The physiological nature of sleep pp. 3-22 Imperial College Press, London.
31. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, (2003) Dimethylarginine dimethyaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108: 3042-3047.
32. Tran CT, Leiper JM, Vallance P, (2003) The DDAH/ADMA/NOS pathway. Atherosclerosis Suppl 4: 33-40.
33. Abe T, Tohgi H, Murata T, Isobe C, Sato C, (2001) Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett 312: 177-179.
34. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, et al. (2003) Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: Role of dimethylarginine dimehtylaminohydrolase. Circ Res 92: 226-233.
35. Quan N, Mhlanga JDM, Whiteside MB, Mccoy AN, Kristensson K, et al. (1999) Chronic overexpression of proinflammatory cytokines and histopathology in the brains of rats infected with Trypanosoma brucei. J Comp Neurol 14: 114-130.
36. Bertini G, Peng ZC, Bentivoglio M, (1996) The chemical heterogeneity of cortical interneurons: Nitric oxide synthase vs. calbindin and paravalbumin immunoreactivity in the rat. Brain Res Bull 39: 261-266.
37. Koliatsos VE, Kecojevic A, Troncoso JC, Gastard MC, Bennett DA, et al. (2006) Early involvement of small inhibitory cortical interneurons in Alzheimer's disease. Acta Neuropathol 112: 147-162.
38. Gow AJ, Chen Q, Hess DT, Day BJ, Ischiropoulos H, et al. (2002) Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J Biol Chem 277: 1746-1755.
39. Cua DJ, Hutchins B, Laface DM, Stohlman SA, Coffman RL, (2001) Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Immunol 166: 602-608.
40. Fliser D, (2005) Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. Eur J Clin Iinvest 35: 71-79.
41. Schroecksnadel K, Weiss G, Stanger O, Teerlinks T, Fuchs D, (2007) Increased Asymmetric dimethylarginine concentrations in stimulated peripheral blood mononuclear. Scand J Immunol 65: 525-529.
42. Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, et al. (2009) Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res 60: 508-514.